Published in Rheumatology (Oxford) on September 27, 2005
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci U S A (2008) 2.18
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest (2009) 2.11
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol (2010) 1.61
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2006) 1.59
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis (2007) 1.42
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther (2006) 1.42
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? Nat Rev Rheumatol (2009) 1.35
Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid (2007) 1.28
Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res (2009) 1.24
Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy. Clin Exp Immunol (2009) 1.23
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity (2012) 1.21
Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis (2005) 1.14
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol (2009) 1.10
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol (2009) 1.07
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol (2009) 1.05
B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 1.00
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol (2006) 0.98
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity (2010) 0.98
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res Ther (2015) 0.98
Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice. PLoS One (2010) 0.94
Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol (2012) 0.89
Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol (2006) 0.86
Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol (2010) 0.85
Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr Nephrol (2012) 0.85
B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford) (2012) 0.85
Autoantibodies in systemic lupus erythematosus. Pediatr Nephrol (2011) 0.83
Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice. Clin Exp Immunol (2014) 0.82
B cells in glomerulonephritis: focus on lupus nephritis. Semin Immunopathol (2007) 0.82
Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B (2012) 0.82
[Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus]. Z Rheumatol (2007) 0.80
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther (2015) 0.80
Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheumatol (2015) 0.79
Biologic treatments for systemic rheumatic diseases. Oral Dis (2008) 0.79
Rituximab in childhood lupus myocarditis. Rheumatol Int (2011) 0.78
How have the past 5 years of research changed clinical practice in paediatric nephrology? Arch Dis Child (2007) 0.78
A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency. Onco Targets Ther (2010) 0.78
Rituximab-induced long-term remission in two children with SLE. Eur J Pediatr (2006) 0.78
Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2010) 0.76
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics (2012) 0.75
Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol (2013) 0.75
Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus. Case Rep Pulmonol (2012) 0.75
Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura. Pediatr Nephrol (2009) 0.75
Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia. Clin Rheumatol (2008) 0.75
Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther (2017) 0.75
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther (1981) 6.71
The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol (1981) 3.99
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med (1993) 3.35
Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. Immunity (1998) 3.16
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol (1995) 2.69
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest (1997) 2.57
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 2.45
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum (2000) 2.28
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Cardiac surgery in Wessex: review of 1000 consecutive open-heart procedures. Br Med J (1976) 2.16
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14
Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford) (1999) 2.14
Mixed connective tissue disease--goodbye to all that. Br J Rheumatol (1992) 2.11
Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med (1988) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Detection of antigen-antibody binding events with the atomic force microscope. Biochemistry (1997) 2.05
Increased inflammatory reactivity in newly formed lining tissue. J Pathol (1983) 2.01
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) (2007) 1.95
Cell-mediated immune response to influenza virus infections in mice. Infect Immun (1976) 1.90
Antibodies to Coxsackie B viruses in congestive cardiomyopathy. Br Heart J (1979) 1.86
Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis (1989) 1.85
Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol (1984) 1.76
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis (2002) 1.74
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med (1982) 1.68
B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum (2006) 1.65
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Associates of health status in patients with systemic lupus erythematosus. J Rheumatol (1999) 1.62
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis (2007) 1.62
Light microscopic characterization of the fibroblast-like synovial intimal cell (synoviocyte). Arthritis Rheum (1992) 1.60
A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.60
Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford) (2007) 1.59
Characterization of a yeast mitochondrial promoter by deletion mutagenesis. Proc Natl Acad Sci U S A (1985) 1.59
Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients. J Clin Invest (1985) 1.59
Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis (1987) 1.53
Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum (1984) 1.53
Analysis of transcriptional initiation of yeast mitochondrial DNA in a homologous in vitro transcription system. Cell (1982) 1.53
Monitoring and interpreting the intrinsic features of somatic hypermutation. Immunol Rev (1998) 1.51
Clinical outcome after one year following samarium-153 particulate hydroxyapatite radiation synovectomy. Scand J Rheumatol (1996) 1.50
Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. Lab Invest (1993) 1.50
The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol (1995) 1.49
Demonstration of bone marrow derived cells in synovial lining by means of giant intracellular granules as genetic markers. Ann Rheum Dis (1982) 1.49
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Scand J Immunol (1989) 1.49
Diagnostic categories in rheumatology. Ann Rheum Dis (1987) 1.49
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
Sjögren's syndrome: association with type-1 diabetes mellitus. Br J Rheumatol (1989) 1.48
Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients. Rheumatology (Oxford) (2008) 1.48
Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum (1985) 1.48
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) (2002) 1.47
Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet (1988) 1.46
Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet (1975) 1.46
The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.45
Thyroid autoimmunity in systemic lupus erythematosus: the clinical significance of a fluctuating course. Br J Rheumatol (1995) 1.44
Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol (2001) 1.44
Muscle changes in ankylosing spondylitis. Br J Rheumatol (1983) 1.43
Aberrant control of galactosyltransferase in peripheral B lymphocytes and Epstein-Barr virus transformed B lymphoblasts from patients with rheumatoid arthritis. J Rheumatol (1993) 1.43
Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS) Br J Rheumatol (1993) 1.42
Identification of a single transcriptional initiation site for the glutamic tRNA and COB genes in yeast mitochondria. Proc Natl Acad Sci U S A (1983) 1.42
Where is the evidence? CMAJ (1993) 1.40
Systemic lupus erythematosus--disease activity, severity, treatment and costs. J Rheumatol (1994) 1.39
Initiation of transcription of the yeast mitochondrial gene coding for ATPase subunit 9. Nucleic Acids Res (1983) 1.39
Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) (2006) 1.39
Muscle strength and pre-osteomalacia in vegetarian Asian women. Lancet (1982) 1.39
A comparison of the performance of two types of infusion device. Anaesthesia (1992) 1.39
A clinical and echocardiographic study of patients with the hypermobility syndrome. Ann Rheum Dis (1981) 1.39
Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) (2003) 1.38
Research and training review of the use of LAS, LAT and flexible training positions. Rheumatology (Oxford) (2001) 1.38
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) (2002) 1.37
Mycobacteria and autoimmunity. Immunol Today (1988) 1.36
An immunohistological study of secondary Sjögren's syndrome. Ann Rheum Dis (1984) 1.36
Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett (1980) 1.36
Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology (1995) 1.34
Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum (2000) 1.34
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Characterization of polymyositis infiltrates using monoclonal antibodies to human leucocyte antigens. Clin Exp Immunol (1981) 1.33
Atypical prion protein in sheep brain collected during the British scrapie-surveillance programme. J Gen Virol (2006) 1.32
An induced extracellular matrix protein reverses the polarity of band 3 in intercalated epithelial cells. Cell (1994) 1.31
SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol (1996) 1.30
Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS), and primary SS. J Rheumatol (1998) 1.30
Coxsackie B neutralisation titres in polymyositis/dermatomyositis. Lancet (1977) 1.28
Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem (1999) 1.26
Cytokines and systemic lupus erythematosus. Ann Rheum Dis (2000) 1.26
Haematological manifestations of systemic lupus erythematosus. Blood Rev (1993) 1.25
Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J (2004) 1.25
A comparative study of the cellular, exudative and histological responses to carrageenan, dextran and zymosan in the mouse. Int J Tissue React (1991) 1.25
Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2001) 1.25
Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumatology (Oxford) (2003) 1.24
Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy. Clin Exp Immunol (1983) 1.24
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) (2004) 1.24
Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP. J Pharmacol Exp Ther (1984) 1.23
The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) (2004) 1.23
The mosaic of autoimmunity. Immunol Today (1989) 1.23